Skip to main content

Anti-Cancer Drug Design is now published as Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics.

Publisher: Cognizant Communication Corporation

Volume 14, Number 6, 1999
Purchase this issue

Virus-detected enzyme prodrug therapy using CB1954
pp. 461-472(12)
Authors: Grove, JI; Searle, PF; Weedon, SJ; Green, NK; McNeish, IA; Kerr, DJ


Antitumour prodrug development using cytochrome P450 (CYP) mediated activation
pp. 473-486(14)
Authors: Patterson, LH; McKeown, SR; Robson, T; Gallagher, R; Raleigh, SM; Orr, S


Intensely cytotoxic anthracycline prodrugs: galactosides
pp. 507-515(9)
Authors: Bakina, E; Farquhar, D


Prodrugs for antibody- and gene-directed enzyme prodrug therapies (ADEPT and GDEPT)
pp. 517-538(22)
Authors: Niculescu-Duvaz, I; Friedlos, F; Niculescu-Duvaz, D; Davies, L; Springer, CJ


Synthesis and antitumor activities of amino acid prodrugs of amino-combretastatins
pp. 539-548(10)
Authors: Ohsumi, K; Hatanaka, T; Nakagawa, R; Fukuda, Y; Morinaga, Y; Suga, Y; Nihei, Y; Ohishi, K; Akiyama, Y; Tsuji, T


The complete issue is available for purchase


Purchasing this issue will give you access to all of the articles listed above for 2 days. You may also purchase articles individually by visiting the abstract page of the article. The exact price (including tax) will be displayed in your shopping cart before you check out. You will be able to remove this item from your shopping cart at any time before you have completed check-out.

Add to cart

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more